Singulex heads for $86.25M flotation

Singulex, a diagnostics company based in Alameda, CA, has filed for an $86.25 million IPO. According to the San Francisco Business Times, the company promises a test that can measure previously undetectable levels of cytokines, blood biomarkers that could indicate an increased risk of heart attack. The company is designing and developing a second-generation digital immunoassay monitoring platform, which could come into use in its own laboratories in 2014, and be commercially available by 2016. Nasdaq overview | Article

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.